Iovance Biotherp Stock Price, News & Analysis

Iovance Biotherapeutics (NASDAQ: IOVA) reported strong financial results for Q4 and FY2024. Total product revenue reached $73.7M in Q4 and $164.1M in FY24, hitting the upper end of guidance. The company's flagship product Amtagvi generated $48.7M in Q4 and $103.6M in FY24 revenue, while Proleukin contributed $25.0M in Q4 and $60.5M in FY24.

The company reaffirmed its FY25 revenue guidance of $450M-$475M and expects cash burn under $300M. With approximately $422M in cash as of February 2025, Iovance is funded into H2 2026. The company anticipates 2025 regulatory approvals for Amtagvi in the UK, EU, and Canada.

Q4 2024 net loss was $78.6M ($0.26/share), improved from $116.4M ($0.45/share) in Q4 2023. FY24 net loss was $372.2M ($1.28/share), better than $444.0M ($1.89/share) in FY23.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for 71 new, non-executive employees on February 21, 2025. The grants cover 328,730 shares of common stock, with an exercise price of $5.78 per share, matching the closing price on the grant date.

The awards were issued under the company's Amended and Restated 2021 Inducement Plan, which was last updated on November 22, 2024. The stock options follow a three-year vesting schedule: one-third vests on the first employment anniversary, with the remaining shares vesting in eight quarterly installments over the following two years, contingent on continued employment.

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has scheduled its fourth quarter and full year 2024 financial results announcement for February 27, 2025.

The company will host a live audio webcast at 4:30 p.m. EST on the same day to discuss results and provide corporate updates. Additionally, Iovance will participate in two upcoming healthcare conferences: TD Cowen's 45th Annual Health Care Conference on March 3, 2025, and Barclays 27th Annual Global Healthcare Conference on March 13, 2025.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement grants for its new Chief Commercial Officer, Daniel Kirby. The grants include stock options and restricted stock units covering up to 305,000 shares of common stock, approved on February 10, 2025.

The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, with stock options exercise price set at the closing price on the grant date. The vesting schedule spans three years, with one-third vesting on the first anniversary and the remaining shares vesting in eight quarterly installments over two years. Some restricted stock awards may vest based on performance milestones tied to financial results rather than time-based vesting.

Iovance Biotherapeutics (NASDAQ: IOVA) has appointed Dan Kirby as Chief Commercial Officer in a newly created role, effective February 10, 2025. Kirby brings extensive experience in cell therapy commercialization, having previously served as Chief Commercial Officer at Orca Bio and Omeros He also held leadership positions at Celgene (now Bristol-Myers Squibb), Juno Therapeutics, Medivation (now Pfizer), and Amgen.

The appointment comes as Iovance, a commercial biotechnology company specializing in polyclonal tumor infiltrating lymphocyte (TIL) therapies, focuses on expanding the U.S. launch of Amtagvi and growing Proleukin sales globally. Kirby's expertise includes market access, reimbursement, marketing, and commercial strategy development for cell therapy products.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for 41 new, non-executive employees on January 16, 2025. The grants cover 224,550 shares of common stock with an exercise price of $5.76 per share, matching the closing price on the grant date.

The awards were issued under the company's Amended and Restated 2021 Inducement Plan, which was last updated on November 22, 2024. The stock options follow a three-year vesting schedule, with one-third vesting on the first employment anniversary and the remaining shares vesting in eight quarterly installments over the following two years, contingent on continued employment.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for 48 new, non-executive employees on December 19, 2024. The grants cover 203,980 shares of common stock with an exercise price of $7.22 per share, matching the closing price on the grant date. These options were awarded under the company's Amended and Restated 2021 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4). The options feature a three-year vesting schedule, with one-third vesting on the first employment anniversary and the remaining portions vesting quarterly over the following two years.

Iovance Biotherapeutics (NASDAQ: IOVA) has promoted Dr. Raj Puri to the newly created position of Chief Regulatory Officer. Dr. Puri, who joined Iovance in March 2022 as Executive Vice President of Regulatory Strategy and Translational Medicine, played a key role in securing regulatory approval for Amtagvi™ in the United States and advancing submissions in multiple international markets. The company aims to address more than 20,000 patients annually with previously treated advanced melanoma starting in 2025. Dr. Puri brings over 33 years of FDA experience, including 19 years as director of the Division of Cellular and Gene Therapies in the FDA's Center for Biologics Evaluation and Research.

Iovance Biotherapeutics reported strong Q3 2024 results with $58.6M in total product revenue, including $42.1M from Amtagvi and $16.5M from Proleukin sales. The company reaffirmed its guidance of $160-165M for FY24 and $450-475M for FY25 in total product revenue. Since Amtagvi's launch in February 2024, 146 patients have been infused, with 82 in Q3 alone. The company has $403.8M in cash position, expected to fund operations into early 2026. Marketing applications for Amtagvi are under review in the UK, EU, and Canada, with potential approvals starting in 1H2025.